Cheaper cancer care therapy earns big bucks for pharma company

ImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ₹12 crore in profit before tax in FY25. Its NexCAR19, an affordable CAR-T therapy, has been administered to over 350 patients across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7auwHQG
via IFTTT